

Leadership

Chair:	Sapna P. Patel, ML
Vice-Chair:	Roger S. Lo, MD, PhD
Executive Officer:	Christopher W. Ryan, MD
Statisticians:	Michael Wu, PhD
	James Moon, MS
	Gabby Lopez, MS
	Matt Chansky, BS
Scientific Leadership	
Translational Medicine:	William E. Carson, III, MD
Radiation Oncology:	TBC
Surgery:	John Robert Hyngstrom, MD
Dermatology:	TBC
Imaging:	TBC
Medical Oncology:	TBC
Pathology:	TBC
Non-Melanoma Skin Cancer:	Nikhil I. Khushalani, MD
Early Therapeutics:	TBC
SWOG's ECOG Liaisons:	Thach-Giao Truong, MD
ECOG's SWOG Liaisons:	David H. Lawson, MD
	Michael Lowe, MD
Designates	
Prevention:	Sancy Leachman, MD, PhD
Data Coordinator:	Michele Counts, BS
	Tonya Johnson, BS
Oncology Research Professionals:	
CRA:	Kathryn Allen, BA, CCRF
Nurse:	TBC
Patient Advocate:	Sara Selig
Pharmaceutical Science:	Sun "Coco" Yang, PharmD, PhD
	_
Protocol Project Manager:	Catrina De Los Santos-Mireles
Clinical Trials Program Manager:	

Time/Location

Saturday, September 20, 2025 11:30 a.m. - 1:30 p.m. Room: Regency D (Ballroom Level, West Tower)

Keynote Speaker: Inside Out - Gut Check with Monty Pal

Monty Pal, MD, FASCO
Professor & Vice Chair of Academic Affairs
Department of Medical Oncology & Experimental Therapeutics
City of Hope Comprehensive Cancer Center

Active Studies

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 4/8/22.

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 9/10/15.

CTSU/EA6192, "The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH." SWOG Champion: Dr. Truong. Activated:10/23/20.

A091903, "A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma." SWOG Champion: K. Tsai, MD (SWOG) Activated 6/1/22. Temporarily Closed to Accrual as of 10/10/23

Studies in Development

52431, "Randomized, open-label, phase III study of anti-PD-1, anti-CTLA-4, and anti-LAG-3 antibodies in patients with previously untreated unresectable or metastatic melanoma." Dr.Chandra

Closed Studies

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/1/18. Closed to Accrual as of 7/1/24.

<u>\$2000</u>, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 9/23/20. Closed: 6/18/24

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/6/18. Closed: 5/5/22.



- S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 6/4/21.
- S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/2/17. Closed: 11/1/20.
- **S1616**, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent." Dr. VanderWalde. Activated: 7/17/17. Closed: 7/15/20.
- **51404**, "A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma." Dr. Patel. Activated: 10/15/15. Closed: 11/2/17.
- CTSU/EA6134, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/21.
- CTSU/EA6183, "A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D)." SWOG Champion: C. D. Lao, MD, MPh Activated: 2/18/20. Closed: 9/23/22.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Spring 2025 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

<u>S1801</u> Design considerations for randomized comparisons of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy when tumor measurement schedules do not align (SWOG S1801). Othus M, Sharon E, Wu M, Sondak V, Ribas A, Patel S. <u>Clinical Trials</u>, Mar 18:17407745251321371, 2025.

https://pubmed.ncbi.nlm.nih.gov/40099861/

Submitted Manuscripts

- S1512 Neoadjuvant PD-1 blockade in patients with surgically resectable desmoplastic 3 melanoma (SWOG S1512 cohort A)... Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Bartosz Chmielowski, Nikhil I. Khushalani, Joseph Markowitz, Marcus Monroe, Carlo Contreras, Egmidio Medina, Gonzalez C, Baselga-Carretero I, Garcilazo I, Vega-Crespo A, Chen J, Al-Deen N, Patel S, Grossmann K, Sondak V, Sharon E, Moon J, Wu M, Ribas A.. Submitted, 2025.
- S1512 High response rate with single agent anti-PD-1 therapy in patients with unresectable desmoplastic melanoma (SWOG S1512 cohort B). Kendra K, Bellasea S, Eroglu Z, Hu-Lieskovan S, Campbell K, Carson W, Wada D, Plaza J, Sosman J, In G, Ikeguchi A, Hyngstrom J, Brohl A, Khushalani N, Markowitz J, Negrea G, Kasbari S, Doolittle G, Swami U, Roberts T, Medina E, Baselga-Carretero I, Gonzalez C, Garcilazo I, Vega-Crespo A, JChen J, Al-Deen N, Patel S, Sharon E, Moon J, Wu M, Ribas A. Submitted, 2025.



Accrual from trials that are open as of 6/30/2025 or have closed in the prior 18 months, by Institution and Study

	<i>\$2000</i>	S2015	A091903	EA6141	EA6174	EA6192	EA6194
Banner MD Anderson Cancer Center	-	37	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	3	1	1
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	16	-	-
Cancer Research Consortium of West Michigan NCORP	-	105	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	1	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	29	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	3	-	-	-
Columbia University Minority Underserved NCORP	-	7	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	19	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	1	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	14	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	11	-	-	-	-	-
Intermountain Medical Center	-	44	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	5	-	30	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	18	-	-	-	-	-
Moffitt Cancer Center	20	56	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-	-
New Mexico Minority Underserved NCORP	-	4	-	-	-	-	-
Northwell Health NCORP	-	10	-	-	-	-	-
Northwestern University LAPS	-	40	-	1	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	3	33	-	-	3	3	-
Regents of the University of Michigan	2	24	-	1	-	-	-
Saint Joseph Hospital - Cancer Centers of Colorado	-	-	-	-	1	-	-
Sutter Cancer Research Consortium	-	-	-	7	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	17	-	4	8	-	3
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	3	1	-	3	-	-
University of Arkansas for Medical Sciences	-	6	-	-	-	1	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2	4	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	46	-	3	1	-	-
University of Kentucky/Markey Cancer Center	-	13	-	-	-	-	-
University of Nebraska Medical Center	-	3	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	-	-	-	-
University of Rochester LAPS	-	6	-	9	1	-	-
University of Texas Health Science Center at San Antonio	-	3	-	1	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	19	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	32	-	-	8	-	-
Western States Cancer Research NCORP	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	15	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	28	-	8	1	-	-
ALLIANCE	1	120	-	-	-	-	-
ECOG-ACRIN	6	220	-	-	-	-	-
NRG	1	98	-	-	-	-	-
Total	37	1,086	1	73	53	10	4



